Citadel Advisors
NRXP icon

Citadel Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Citadel Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,600
Closed -$5.72K – 15251
2024
Q4 		$5.72K Buy
2,600
+1,600
+160% +$2.15K ﹤0.01% 13843
2024
Q3 		$1.69K Buy
1,000
+150
+18% +$302 ﹤0.01% 13821
2024
Q2 		$2.07K Sell
850
-110
-11% -$391 ﹤0.01% 13738
2024
Q1 		$4.53K Buy
960
+870
+967% +$4.01K ﹤0.01% 13806
2023
Q4 		$414 Sell
90
-340
-79% -$1.12K ﹤0.01% 14034
2023
Q3 		$1.12K Sell
430
-20
-4% -$67 ﹤0.01% 13916
2023
Q2 		$2.18K Sell
450
-660
-59% -$3.97K ﹤0.01% 13815
2023
Q1 		$7.32K Buy
1,110
+260
+31% +$2.63K ﹤0.01% 13736
2022
Q4 		$9.44K Sell
850
-1,600
-65% -$16.1K ﹤0.01% 13683
2022
Q3 		$18K Sell
2,450
-760
-24% -$5.12K ﹤0.01% 12110
2022
Q2 		$19K Sell
3,210
-4,290
-57% -$56.4K ﹤0.01% 12425
2022
Q1 		$184K Sell
7,500
-12,130
-62% -$395K ﹤0.01% 11636
2021
Q4 		$938K Sell
19,630
-17,770
-48% -$1.28M ﹤0.01% 8122
2021
Q3 		$3.47M Buy
+37,400
New +$4.87M ﹤0.01% 5051

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's NRXP Position: Q3 2025 in Review

Citadel Advisors sold out of NRX Pharmaceuticals (NRXP) in Q3 2025, closing a stake of 92,361 shares — an estimated $264K sold.

Citadel Advisors first reported a position in NRXP in Q3 2021 and held it in 6 quarters. The position peaked at $1.25M in Q3 2021. 24 funds tracked by Wall St. Rank hold NRXP as of Q3 2025.

  • Citadel Advisors reported no remaining NRX Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 92,361 NRX Pharmaceuticals shares in Q3 2025, an estimated $264K.
  • Citadel Advisors first reported a position in NRX Pharmaceuticals in Q3 2021 and held it in 6 quarters.
  • Citadel Advisors's NRX Pharmaceuticals position peaked at $1.25M in Q3 2021.
  • 24 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.